Quantcast
Last updated on April 16, 2014 at 11:09 EDT

Latest Piperidines Stories

2014-04-14 12:34:34

RIDGEFIELD, Conn. and INDIANAPOLIS, April 14, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (Lilly; NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) accepted the filing of the New Drug Application (NDA) for the investigational combination tablet of empagliflozin and linagliptin for the treatment of adults with type 2 diabetes (T2D). If granted approval by the FDA, this combination will bring together, for the first time into...

2014-04-12 23:00:44

Arkansas Attorney General Has Asked State Supreme Court to Reconsider Its Decision to Overturn $1.2 Billion Risperdal Lawsuit Verdict Columbus, OH (PRWEB) April 12, 2014 The Risperdal lawsuit lawyers at Wright & Schulte LLC, note that the Arkansas Attorney General has filed a petition with the state’s Supreme Court asking it to reconsider a recent decision which overturned a $1.2 billion Risperdal lawsuit verdict awarded to the state in 2012 over the marketing of the antipsychotic...

2014-04-11 15:08:25

Schizophrenia is a severe disease for which there is still no effective medical treatment. In an attempt to understand exactly what happens in the brain of schizophrenic people, researchers from the University of Southern Denmark have analysed proteins in the brains of rats that have been given hallucinogenic drugs. This may pave the way for new and better medicines. Seven per cent of the adult population suffer from schizophrenia, and although scientists have tried for centuries to...

2014-04-10 23:01:50

The Firm is representing men and boys in Risperdal lawsuits who allegedly developed gynecomastia, or male breast growth, due to Risperdal. New York, New York (PRWEB) April 10, 2014 As Risperdal lawsuits (http://www.risperdallawsuitcenter.com/ ) continue to mount in U.S. courts, Bernstein Liebhard LLP notes the publication of a new study which reveals the off-label use of atypical antipsychotic drugs like Risperdal is rising among children in foster care. The research, which was published...

2014-04-08 23:32:37

No-cost consultations from a national network of attorneys are now available to consumers of all ages who may be seeking compensation over allegations of gynecomastia, other side effects. San Diego, CA (PRWEB) April 08, 2014 http://www.resource4thepeople.com/defectivedrugs/risperdal.html Resource4thePeople announced today that its national network of attorneys has expanded its free legal consultations over allegations that the antipsychotic medication Risperdal may cause a breast-growth...

2014-04-06 23:01:17

Study Released as Risperdal Lawsuits Alleging Use of Antipsychotic Drug Caused Gynecomastia (Male Breast Growth) in Men and Boys Continue to Move Forward in Pennsylvania Columbus, OH (PRWEB) April 06, 2014 Wright & Schulte LLC, an experienced law firm representing clients in Risperdal lawsuits, notes that a new study has linked use of the atypical antipsychotic medication to gynecomastia, or male breast growth. The release of the study, which was presented in March at the 2014 Annual...

2014-04-04 23:01:22

The Firm is actively filing Risperdal lawsuits on behalf of men and boys who allegedly suffered gynecomastia, or male breast development, due to their use of Risperdal. New York, New York (PRWEB) April 04, 2014 As Risperdal lawsuits (http://www.risperdallawsuitcenter.com/ ) continue to mount in U.S. courts, Bernstein Liebhard LLP notes that the Arkansas Attorney General has announced his intention to seek the reinstatement of a $1.2 billion Risperdal fine overturned by the state’s...

2014-04-02 23:01:07

The Firm continues to investigate Risperdal lawsuits that allege the atypical antipsychotic drug caused male breast development, or gynecomastia. New York, New York (PRWEB) April 02, 2014 The nationwide law firm of Bernstein Liebhard LLP is actively filing Risperdal lawsuits (http://www.risperdallawsuitcenter.com/) on behalf of individuals who allegedly suffered gynecomastia, or male breast growth, due to their use of the atypical antipsychotic. On March 26, 2014, the Firm filed a claim...

2014-04-01 16:25:48

CUPERTINO, Calif., April 1, 2014 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that data for POSIDUR((TM)) (SABER(®)-Bupivacaine), an investigational drug for administration into the surgical site to produce post-surgical analgesia, is being presented at the 39(th) Annual American Society of Regional Anesthetic and Pain Medicine Meeting. The meeting will be held on April 3-6 at the Sheraton Chicago Hotel and Towers in Chicago....

2014-04-01 08:30:33

- Prasco to market the Authorized Generic of EVISTA® in the United States CINCINNATI, April 1, 2014 /PRNewswire/ -- Prasco Laboratories, announced today it has signed a marketing and distribution agreement with Eli Lilly and Company (NYSE: LLY) to market the Authorized Generic (AG) version of EVISTA(®) (raloxifene hydrochloride tablets), in 60 mg strength in the United States. Prasco will begin shipping the product immediately. The financial terms of the agreement were not...